Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4579709 | 1.00 | CETP (1.00) | CETP | |
| SCHEMBL710242 | 0.99 | CETP (0.98) | CETP | |
| SCHEMBL710241 | 0.99 | CETP (0.98) | CETP | |
| SCHEMBL2610201 | 0.90 | CETP (0.98) | CETP | |
| SCHEMBL712339 | 0.90 | CETP (1.00) | CETP | |
| SCHEMBL712340 | 0.90 | CETP (1.00) | CETP | |
| SCHEMBL29352086 | 0.90 | CETP (1.00) | CETP | |
| SCHEMBL20768034 | 0.90 | CETP (1.00) | CETP | |
| SCHEMBL19229666 | 0.90 | CETP (1.00) | CETP | |
| SCHEMBL10038003 | 0.90 | CETP (0.81) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142728-A1 | CHEMICAL COMPOUND AND ITS USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20080194609-A1 | Chemical Compound and Its Use | BAYER HEATHCARE AG (DE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194609-A1 | Chemical Compound and Its Use | BAYER HEATHCARE AG (DE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194609-A1 | Chemical Compound and Its Use | BAYER HEATHCARE AG (DE) | 2008-08-14 | — | — | US | disclosed |
| EP-1828136-A1 | (5S) -3-[(S)-FLUORO (4-TRIFLUOROMETHYLPHENYL) METHYL]-5,6,7,8-TETRAHYDROQUINOLINE-5-OL DERIVATIVES AND USE THEREOF AS CETP INHIBITORS | Bayer HealthCare AG (DE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006072362-A1 | (5S) -3-[(S)-FLUORO (4-TRIFLUOROMETHYLPHENYL) METHYL]-5,6,7,8-TETRAHYDROQUINOLINE-5-OL DERIVATIVES AND USE THEREOF AS CETP INHIBITORS | BAYER HEALTHCARE AG (DE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142728-A1 | CHEMICAL COMPOUND AND ITS USE | CETP, MTTP, LCAT | CETP 1/4885 |
| US-20080194609-A1 | Chemical Compound and Its Use | CETP, MTTP, LCAT | CETP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.